SOURCE: Amarillo Biosciences, Inc.

March 03, 2008 10:25 ET

Amarillo Biosciences Oral Warts Study Enrollment at Halfway Point

The Patient Recruiting Agency Retained to Accelerate Enrollment

AMARILLO, TX--(Marketwire - March 3, 2008) - Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced that enrollment for its Phase 2 oral warts clinical trial had reached 40 patients, halfway towards the goal of enrolling 80 patients in a study testing low dose oral interferon alpha lozenges administered orally to human immunodeficiency virus (HIV) positive subjects with oral warts. Thirteen clinical sites are participating in the study in: Augusta (GA), Baltimore, Boston, Chicago, Dallas, Ft. Lauderdale, Lexington (KY), New Orleans, New York City, Newark, Philadelphia, San Antonio and San Francisco. Interested patients are urged to contact Martin Cummins, Vice President, Clinical and Regulatory Affairs, via phone: 806-376-1741 ext. 14 or email: mcummins@amarbio.com for clinical site information.

In a related development, ABI announced that it has retained The Patient Recruiting Agency™ (TPRA) of Austin, Texas to accelerate enrollment in its Phase 2 clinical trial of oral warts in HIV positive patients. TPRA will design a multi-media campaign that will include print, television and Internet advertising, plus a grassroots awareness effort. The effort will be supported by a study-specific website. Advertisements will start running in March 2008 in the media markets in which the company has clinical sites.

Two previous studies demonstrated the ability of interferon alpha lozenges to reduce oral wart load in HIV-positive patients. If, as anticipated, ABI's new study demonstrates the efficacy and safety of this treatment regimen, ABI intends to conduct a Phase 3 study before filing an NDA (New Drug Application), seeking marketing approval for interferon alpha lozenges in the treatment of oral warts in HIV-positive patients.

About Amarillo Biosciences, Inc.

Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 11% of Amarillo Biosciences shares and has provided over $18 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including Chronic cough, influenza, and opportunistic infections in patients who are HIV positive. In its 23-year history, the Company has invested nearly $39 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for interferon. Additional information is available on the web site at http://www.amarbio.com/.

About The Patient Recruiting Agency

The Patient Recruiting Agency™ (TPRA) specializes in the production and placement of customized direct-to-patient advertising and technological solutions to support Sponsors, CROs, SMOs, and Investigators with their recruiting and retention efforts. TPRA has completed over 1,800 recruiting campaigns in multiple languages supporting over 90 different indications. What makes TPRA unique is that all production, media placement, online efforts, and tracking and management technologies are created and implemented by its own "in house" team with no outsourcing. This operating model significantly reduces the overall recruiting costs for the sponsor and offers greater flexibility for quicker campaign development with greater outreach impact. The end result for the sponsor is more studies will be completed on time for less money.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" of the Company's Form 10-KSB for the year ended December 31, 2007.

Contact Information

  • Investor Relations:
    Philippe Niemetz
    PAN Consultants, Ltd.
    e-mail: p.niemetz@panconsultants.com
    Tel: 800-477-7570
    212-344-6464
    Fax: 212-618-1276

    Joseph M. Cummins, DVM, PhD
    Amarillo Biosciences, Inc.
    e-mail: jcummins@amarbio.com
    Tel: 806-376-1741 x 13
    Fax: 806-376-9301